Search Results
Panelists Discuss Access to CAR-T for Patients with Myeloma
Bispecific Versus CAR T-Cell Therapy for Myeloma and Bridging Therapy Needs for CAR-T
Challenges in access to commercial CAR-T therapies in multiple myeloma
Is There an Ideal Space for Allogeneic CAR-T Products for Myeloma?
BCMA-Targeted CAR-Ts and Their Role in Late-Relapse Multiple Myeloma
BCMA Bispecific Toxicities, Access Considerations
Hitting the BCMA Target in Multiple Myeloma
Real-World CAR-T Outcomes, Use of Ide-cel, Cilta-cel for Myeloma
Ciltacabtagene Autoleucel and CARTITUDE Findings in Relapsed/Refractory Myeloma
The curative potential of CAR-T therapy in multiple myeloma
CAR-T Therapy, CARTITUDE-1 ciltacabtagene autoleucel in RRMM Patients | Yi Lin, MD, PhD | ASCO 2023
IMWG Conference Series: Reporting from ASH 2022
